A synthetic lethal screen identifies ATR-inhibition as a novel therapeutic approach for POLD1-deficient cancers

Oncotarget

Volumn 7, Issue 6, 2016, Pages 7080-7095

  Hocke, Sandra ^a   Guo, Yang ^a   Job, Albert ^b   Orth, Michael ^a   Ziesch, Andreas ^a   Lauber, Kirsten ^a   De Toni, Enrico N ^a   Gress, Thomas M ^b   Herbst, Andreas ^a   Göke, Burkhard ^a   Gallmeier, Eike ^a,b  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

ATR; DNA repair; POLD1; Synthetic lethality; Targeted therapy

Indexed keywords

7 HYDROXYSTAUROSPORINE; CASPASE 3; CASPASE 8; CASPASE 9; DNA POLYMERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE RELATED KINASE ATP; POLD1 PROTEIN; UNCLASSIFIED DRUG; ATM PROTEIN; ATR PROTEIN, HUMAN; DNA DIRECTED DNA POLYMERASE GAMMA; DNA LIGASE; ENZYME INHIBITOR; H2AFX PROTEIN, HUMAN; HISTONE; POLD1 PROTEIN, HUMAN; PROTEIN KINASE; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER THERAPY; CARCINOGENESIS; CELL CYCLE ARREST; COLORECTAL CANCER; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; ENDOMETRIUM CANCER; ENZYME ACTIVITY; ENZYME INHIBITION; GENOTYPE; HUMAN; HUMAN CELL; MOLECULAR LIBRARY; PROTEIN DEPLETION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; ANTAGONISTS AND INHIBITORS; CELL CYCLE; CELL NUCLEUS; CELL PROLIFERATION; CHEMISTRY; COLORECTAL NEOPLASMS; DEFICIENCY; DRUG EFFECTS; FLUOROMETRY; GENETICS; HIGH THROUGHPUT SCREENING; METABOLISM; MUTATION; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ATAXIA TELANGIECTASIA MUTATED PROTEINS; BLOTTING, WESTERN; CELL CYCLE; CELL NUCLEUS; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DNA DAMAGE; DNA POLYMERASE III; DNA REPAIR; DNA REPAIR ENZYMES; ENZYME INHIBITORS; FLUOROMETRY; HIGH-THROUGHPUT SCREENING ASSAYS; HISTONES; HUMANS; MUTATION; PROTEIN KINASES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 84971324579     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6857     Document Type: Article

References (68)

1. Pino MS and Chung DC. The chromosomal instabil-ity pathway in colon cancer. Gastroenterology. 2010; 138:2059-2072.
2. Helleday T, Petermann E, Lundin C, Hodgson B and Sharma RA. DNA repair pathways as targets for cancer therapy. Nature reviews Cancer. 2008; 8:193-204.
3. Kaelin WG, Jr. The concept of synthetic lethality in the con-text of anticancer therapy. Nature reviews Cancer. 2005; 5:689-698.
4. Chan DA and Giaccia AJ. Harnessing synthetic lethal inter-actions in anticancer drug discovery. Nature reviews Drug discovery. 2011; 10:351-364.
5. Sonnenblick A, de Azambuja E, Azim HA, Jr. and Piccart M. An update on PARP inhibitors--moving to the adjuvant setting. Nature reviews Clinical oncology. 2015; 12:27-41.
6. Scott CL, Swisher EM and Kaufmann SH. Poly (ADP-ribose) polymerase inhibitors: recent advances and future development. J Clin Oncol. 2015; 33:1397-1406.
7. Martin SA, McCabe N, Mullarkey M, Cummins R, Burgess DJ, Nakabeppu Y, Oka S, Kay E, Lord CJ and Ashworth A. DNA polymerases as potential therapeutic targets for can-cers deficient in the DNA mismatch repair proteins MSH2 or MLH1. Cancer cell. 2010; 17:235-248.
8. Lok BH, Carley AC, Tchang B and Powell SN. RAD52 inactivation is synthetically lethal with deficiencies in BRCA1 and PALB2 in addition to BRCA2 through RAD51-mediated homologous recombination. Oncogene. 2013; 32:3552-3558.
9. Al-Ahmadie H, Iyer G, Hohl M, Asthana S, Inagaki A, Schultz N, Hanrahan AJ, Scott SN, Brannon AR, McDermott GC, Pirun M, Ostrovnaya I, Kim P, et al. Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy. Cancer discovery. 2014; 4:1014-1021.
10. Paulsen RD and Cimprich KA. The ATR pathway: fine-tuning the fork. DNA repair. 2007; 6:953-966.
11. Zhou BB and Elledge SJ. The DNA damage response: put-ting checkpoints in perspective. Nature. 2000; 408:433-439.
12. Cimprich KA and Cortez D. ATR: an essential regulator of genome integrity. Nature reviews Molecular cell biology. 2008; 9:616-627.
13. Weber AM and Ryan AJ. ATM and ATR as therapeutic targets in cancer. Pharmacology & therapeutics. 2015; 149:124-38. doi: 10.1016/j.pharmthera.2014.12.001.
14. Gallmeier E, Hermann PC, Mueller MT, Machado JG, Ziesch A, De Toni EN, Palagyi A, Eisen C, Ellwart JW, Rivera J, Rubio-Viqueira B, Hidalgo M, Bunz F, et al. Inhibition of ataxia telangiectasia-and Rad3-related function abrogates the in vitro and in vivo tumorigenic-ity of human colon cancer cells through depletion of the CD133(+) tumor-initiating cell fraction. Stem cells (Dayton, Ohio). 2011; 29:418-429.
15. Wagner JM and Kaufmann SH. Prospects for the use of ATR inhibitors to treat cancer. Pharmaceuticals. 2010; 3:1311-1334.
16. Reaper PM, Griffiths MR, Long JM, Charrier JD, Maccormick S, Charlton PA, Golec JM and Pollard JR. Selective killing of ATM-or p53-deficient cancer cells through inhibition of ATR. Nature chemical biology. 2011; 7:428-430.
17. Sultana R, Abdel-Fatah T, Perry C, Moseley P, Albarakti N, Mohan V, Seedhouse C, Chan S and Madhusudan S. Ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase inhibition is synthetically lethal in XRCC1 deficient ovarian cancer cells. PloS one. 2013; 8:e57098.
18. Mohni KN, Kavanaugh GM and Cortez D. ATR pathway inhibition is synthetically lethal in cancer cells with ERCC1 deficiency. Cancer research. 2014; 74:2835-2845.
19. Menezes DL, Holt J, Tang Y, Feng J, Barsanti P, Pan Y, Ghoddusi M, Zhang W, Thomas G, Holash J, Lees E and Taricani L. A synthetic lethal screen reveals enhanced sensitiv-ity to ATR inhibitor treatment in mantle cell lymphoma with ATM loss-of-function. Mol Cancer Res. 2015; 13:120-129.
20. Toledo LI, Murga M, Zur R, Soria R, Rodriguez A, Martinez S, Oyarzabal J, Pastor J, Bischoff JR and Fernandez-Capetillo O. A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-asso-ciated mutations. Nature structural & molecular biology. 2011; 18:721-727.
21. Gilad O, Nabet BY, Ragland RL, Schoppy DW, Smith KD, Durham AC and Brown EJ. Combining ATR suppres-sion with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner. Cancer research. 2010; 70:9693-9702.
22. Wilsker D and Bunz F. Loss of ataxia telangiecta-sia mutated-and Rad3-related function potentiates the effects of chemotherapeutic drugs on cancer cell survival. Molecular cancer therapeutics. 2007; 6:1406-1413.
23. Hurley PJ, Wilsker D and Bunz F. Human cancer cells require ATR for cell cycle progression following exposure to ionizing radiation. Oncogene. 2007; 26:2535-2542.
24. Gallmeier E, Hucl T, Calhoun ES, Cunningham SC, Bunz F, Brody JR and Kern SE. Gene-specific selection against experimental fanconi anemia gene inactivation in human cancer. Cancer biology & therapy. 2007; 6:654-660.
25. Andreassen PR, D'Andrea AD and Taniguchi T. ATR couples FANCD2 monoubiquitination to the DNA-damage response. Genes & development. 2004; 18:1958-1963.
26. Yonemasu R, Minami M, Nakatsu Y, Takeuchi M, Kuraoka I, Matsuda Y, Higashi Y, Kondoh H and Tanaka K. Disruption of mouse XAB2 gene involved in pre-mRNA splicing, transcription and transcription-coupled DNA repair results in preimplantation lethality. DNA repair. 2005; 4:479-491.
27. Lu LY, Wood JL, Minter-Dykhouse K, Ye L, Saunders TL, Yu X and Chen J. Polo-like kinase 1 is essential for early embryonic development and tumor suppression. Molecular and cellular biology. 2008; 28:6870-6876.
28. Rogakou EP, Boon C, Redon C and Bonner WM. Megabase chromatin domains involved in DNA double-strand breaks in vivo. The Journal of cell biology. 1999; 146:905-916.
29. Svetlova M, Solovjeva L and Tomilin N. Mechanism of elimination of phosphorylated histone H2AX from chro-matin after repair of DNA double-strand breaks. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis. 2010; 685:54-60.
30. Murga M, Campaner S, Lopez-Contreras AJ, Toledo LI, Soria R, Montana MF, D'Artista L, Schleker T, Guerra C, Garcia E, Barbacid M, Hidalgo M, Amati B and Fernandez-Capetillo O. Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. Nature struc-tural & molecular biology. 2011; 18:1331-1335.
31. Couch FB, Bansbach CE, Driscoll R, Luzwick JW, Glick GG, Betous R, Carroll CM, Jung SY, Qin J, Cimprich KA and Cortez D. ATR phosphorylates SMARCAL1 to pre-vent replication fork collapse. Genes & development. 2013; 27:1610-1623.
32. Fokas E, Prevo R, Pollard JR, Reaper PM, Charlton PA, Cornelissen B, Vallis KA, Hammond EM, Olcina MM, Gillies McKenna W, Muschel RJ and Brunner TB. Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation. Cell death & disease. 2012; 3:e441.
33. Cortez D, Guntuku S, Qin J and Elledge SJ. ATR and ATRIP: partners in checkpoint signaling. Science (New York, NY). 2001; 294:1713-1716.
34. O'Driscoll M, Ruiz-Perez VL, Woods CG, Jeggo PA and Goodship JA. A splicing mutation affecting expression of ataxia-telangiectasia and Rad3-related protein (ATR) results in Seckel syndrome. Nature genetics. 2003; 33:497-501.
35. Zhang J-H, Chung TD and Oldenburg KR. A simple sta-tistical parameter for use in evaluation and validation of high throughput screening assays. Journal of biomolecular screening. 1999; 4:67-73.
36. Mohni KN, Thompson PS, Luzwick JW, Glick GG, Pendleton CS, Lehmann BD, Pietenpol JA and Cortez D. A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments. PloS one. 2015; 10:e0125482.
37. Higgins GS, Prevo R, Lee YF, Helleday T, Muschel RJ, Taylor S, Yoshimura M, Hickson ID, Bernhard EJ and McKenna WG. A small interfering RNA screen of genes involved in DNA repair identifies tumor-specific radiosen-sitization by POLQ knockdown. Cancer research. 2010; 70:2984-2993.
38. Prindle MJ and Loeb LA. DNA polymerase delta in DNA replication and genome maintenance. Environmental and molecular mutagenesis. 2012; 53:666-682.
39. Michael WM, Ott R, Fanning E and Newport J. Activation of the DNA replication checkpoint through RNA syn-thesis by primase. Science (New York, NY). 2000; 289:2133-2137.
40. Yotov WV, Hamel H, Rivard GE, Champagne MA, Russo PA, Leclerc JM, Bernstein ML and Levy E. Amplifications of DNA primase 1 (PRIM1) in human osteosarcoma. Genes, chromosomes & cancer. 1999; 26:62-69.
41. Pellegrini L. The Pol alpha-primase complex. Sub-cellular biochemistry. 2012; 62:157-169.
42. Hekmat-Nejad M, You Z, Yee MC, Newport JW and Cimprich KA. Xenopus ATR is a replication-dependent chromatin-binding protein required for the DNA replication checkpoint. Current biology : CB. 2000; 10:1565-1573.
43. Pfeiffer P, Goedecke W, Kuhfittig-Kulle S and Obe G. Pathways of DNA double-strand break repair and their impact on the prevention and formation of chromosomal aberrations. Cytogenetic and genome research. 2004; 104:7-13.
44. Burckstummer T, Bennett KL, Preradovic A, Schutze G, Hantschel O, Superti-Furga G and Bauch A. An effi-cient tandem affinity purification procedure for interaction proteomics in mammalian cells. Nature methods. 2006; 3:1013-1019.
45. Sibani S, Price GB and Zannis-Hadjopoulos M. Ku80 binds to human replication origins prior to the assembly of the ORC complex. Biochemistry. 2005; 44:7885-7896.
46. Rampakakis E, Di Paola D and Zannis-Hadjopoulos M. Ku is involved in cell growth, DNA replication and G1-S tran-sition. Journal of cell science. 2008; 121:590-600.
47. Curtin NJ. DNA repair dysregulation from cancer driver to therapeutic target. Nature reviews Cancer. 2012; 12:801-817.
48. Bartek J, Mistrik M and Bartkova J. Thresholds of replica-tion stress signaling in cancer development and treatment. Nature structural & molecular biology. 2012; 19:5-7.
49. Liu Q, Guntuku S, Cui X-S, Matsuoka S, Cortez D, Tamai K, Luo G, Carattini-Rivera S, DeMayo F and Bradley A. Chk1 is an essential kinase that is regulated by Atr and required for the G2/M DNA damage checkpoint. Genes & development. 2000; 14:1448-1459.
50. Ma CX, Janetka JW and Piwnica-Worms H. Death by releasing the breaks: CHK1 inhibitors as cancer therapeu-tics. Trends in molecular medicine. 2011; 17:88-96.
51. Luciani MG, Oehlmann M and Blow JJ. Characterization of a novel ATR-dependent, Chk1-independent, intra-S-phase checkpoint that suppresses initiation of replication in Xenopus. Journal of cell science. 2004; 117:6019-6030.
52. Matsuoka S, Ballif BA, Smogorzewska A, McDonald ER, Hurov KE, Luo J, Bakalarski CE, Zhao Z, Solimini N and Lerenthal Y. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science (New York, NY). 2007; 316:1160-1166.
53. Buisson R, Boisvert JL, Benes CH and Zou L. Distinct but Concerted Roles of ATR, DNA-PK, and Chk1 in Countering Replication Stress during S Phase. Molecular cell. 2015; 59:1011-1024.
54. Oliveira C, Pinto M, Duval A, Brennetot C, Domingo E, Espin E, Armengol M, Yamamoto H, Hamelin R, Seruca R and Schwartz S, Jr. BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency. Oncogene. 2003; 22:9192-9196.
55. Ahmed D, Eide PW, Eilertsen IA, Danielsen SA, Eknaes M, Hektoen M, Lind GE and Lothe RA. Epigenetic and genetic features of 24 colon cancer cell lines. Oncogenesis. 2013; 2:e71.
56. Chen M and Wang J. Initiator caspases in apoptosis signal-ing pathways. Apoptosis. 2002; 7:313-319.
57. Lauber K, Appel HA, Schlosser SF, Gregor M, Schulze-Osthoff K and Wesselborg S. The adapter protein apoptotic protease-activating factor-1 (Apaf-1) is proteolytically pro-cessed during apoptosis. The Journal of biological chemis-try. 2001; 276:29772-29781.
58. Uchimura A, Hidaka Y, Hirabayashi T, Hirabayashi M and Yagi T. DNA polymerase delta is required for early mam-malian embryogenesis. PloS one. 2009; 4:e4184.
59. Song J, Hong P, Liu C, Zhang Y, Wang J and Wang P. Human POLD1 modulates cell cycle progression and DNA damage repair. BMC biochemistry. 2015; 16:14.
60. Roos WP and Kaina B. DNA damage-induced cell death: from specific DNA lesions to the DNA damage response and apoptosis. Cancer letters. 2013; 332:237-248.
61. Fernandez-Capetillo O, Lee A, Nussenzweig M and Nussenzweig A. H2AX: the histone guardian of the genome. DNA repair. 2004; 3:959-967.
62. Flohr T, Dai JC, Büttner J, Popanda O, Hagmüller E and Thielmann HW. Detection of mutations in the DNA poly-merase δ gene of human sporadic colorectal cancers and colon cancer cell lines. International journal of cancer. 1999; 80:919-929.
63. Church DN, Briggs SE, Palles C, Domingo E, Kearsey SJ, Grimes JM, Gorman M, Martin L, Howarth KM, Hodgson SV, Kaur K, Taylor J and Tomlinson IP. DNA polymerase epsilon and delta exonuclease domain mutations in endome-trial cancer. Human molecular genetics. 2013; 22:2820-2828.
64. Palles C, Cazier JB, Howarth KM, Domingo E, Jones AM, Broderick P, Kemp Z, Spain SL, Guarino E, Salguero I, Sherborne A, Chubb D, Carvajal-Carmona LG, et al. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nature genetics. 2013; 45:136-144.
65. COSMIC, Cell, Line and Project. http://cancer.sanger.ac.uk/cell_lines. 2015.
66. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F and Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. Journal of immunological methods. 1991; 139:271-279.
67. Kleeff J, Kornmann M, Sawhney H and Korc M. Actinomycin D induces apoptosis and inhibits growth of pancreatic cancer cells. International journal of cancer Journal international du cancer. 2000; 86:399-407.
68. Arda-Pirincci P and Bolkent S. The role of glucagon-like peptide-2 on apoptosis, cell proliferation, and oxidant-antioxidant system at a mouse model of intestinal injury induced by tumor necrosis factor-alpha/actinomycin D. Molecular and cellular biochemistry. 2011; 350:13-27.